Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 4,273 articles

Articles by Daniel Marsh

Semiconductor Slump Hits Wall Street as Tech Giants Hold Steady
Markets

Semiconductor Slump Hits Wall Street as Tech Giants Hold Steady

Wall Street saw a split Friday as chip stocks tumbled but megacap platforms held firm, with the SOXX dropping 4.67% and Micron falling 4.17% after a previous surge.

SOXX MSFT AAPL AMZN NVDA MU AMD ON SYNA SPY QQQ DIA IWM
EchoStar's ECHO Debut Slumps on AT&T Cash Dependence, SpaceX Index Event
Markets

EchoStar's ECHO Debut Slumps on AT&T Cash Dependence, SpaceX Index Event

EchoStar's new ECHO ticker dropped 6.5% in its first two sessions, with the $20.25B AT&T cash representing 71% of equity. The stock rebounded 1.7% Friday as investors eye deal closing and SpaceX's Russell index addition.

SATS T
SELLAS Life Sciences Soars on Heavy Short Interest Ahead of AML Trial Results
Markets

SELLAS Life Sciences Soars on Heavy Short Interest Ahead of AML Trial Results

SELLAS Life Sciences (SLS) surged 6.3% to $11.19 as short interest climbed to 32.65% of float and trading volume doubled. The company amended executive severance terms and disclosed 78 of 80 events reached in its Phase 3 AML trial.

SLS XBI
Centessa's Final Trade Puts Lilly CVR at 28% of Maximum Value
Markets

Centessa's Final Trade Puts Lilly CVR at 28% of Maximum Value

Centessa's final $40.50 trade implies a 28% value on its non-transferable CVR from the $38/share Lilly buyout, with only drug-approval payouts remaining.

LLY
Can-Fite BioPharma Surges on Japanese Patent Grant for Obesity Drug
Markets

Can-Fite BioPharma Surges on Japanese Patent Grant for Obesity Drug

Can-Fite BioPharma shares surged 17% premarket after Japan allowed a patent for Namodenoson in obesity, but the company's $6.61M market cap remains near the NYSE American delisting threshold.

EWJ
Amazon Drops Below Analyst Target Amid Cloud Selloff and EU Scrutiny
Markets

Amazon Drops Below Analyst Target Amid Cloud Selloff and EU Scrutiny

Amazon shares closed Thursday at $227.01, below the lowest analyst target of $230, amid a cloud-led selloff and EU scrutiny.

AMZN MSFT
BlackBerry Surges as QNX Revenue Soars 26%, AI Premium Drives $1B Market Cap Increase
Analysis

BlackBerry Surges as QNX Revenue Soars 26%, AI Premium Drives $1B Market Cap Increase

BlackBerry's market cap jumped $1 billion after QNX revenue rose 26% and fiscal 2027 guidance increased. Analysts raised targets, citing faster operating leverage and AI potential.

BB RJF
Nokia shares tumble as AI rally fades; €18B wiped out since June peak
Markets

Nokia shares tumble as AI rally fades; €18B wiped out since June peak

Nokia shares slid to €11.74 in Helsinki, extending a pullback that has erased about €18B in market value since the June 3 high. Investors await Q2 results due July 23.

AMZN
ON Semiconductor Plunges 14% on Synaptics Stock Deal; Target Shares Rally
Markets

ON Semiconductor Plunges 14% on Synaptics Stock Deal; Target Shares Rally

ON Semiconductor shares dropped 14.2% premarket after announcing an all-stock deal to buy Synaptics, erasing about $6.6 billion in market cap. Synaptics shares gained 4.5%.

ON SYNA SOXX
SoFi Holds Near $17 as Russell Rebalancing Looms
Markets

SoFi Holds Near $17 as Russell Rebalancing Looms

SoFi shares remain near $17.30 despite an AI investing platform launch, as investors focus on Friday's Russell index rebalancing that could drive significant volume and volatility.

SOFI
INVO Fertility Surges on Clinic Buyout and Nasdaq Compliance
Markets

INVO Fertility Surges on Clinic Buyout and Nasdaq Compliance

INVO Fertility shares jumped 51.6% premarket after the company took full control of its Birmingham clinic for $1 upfront and regained Nasdaq compliance.

IVF
INLIF Pre-Market Volume Surges 81x Shares Outstanding After Reverse Split
Markets

INLIF Pre-Market Volume Surges 81x Shares Outstanding After Reverse Split

INLIF (NASDAQ:INLF) surged in pre-market trading with volume exceeding 1 billion shares, 81 times its outstanding shares, as the stock remains well below Nasdaq's $1 minimum bid requirement.

INLF